TD Private Client Wealth LLC Increases Stake in IQVIA Holdings Inc. (NYSE:IQV)

TD Private Client Wealth LLC raised its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 8.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,031 shares of the medical research company’s stock after buying an additional 80 shares during the quarter. TD Private Client Wealth LLC’s holdings in IQVIA were worth $244,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Toronto Dominion Bank grew its stake in IQVIA by 11.3% during the 3rd quarter. Toronto Dominion Bank now owns 60,416 shares of the medical research company’s stock valued at $14,317,000 after acquiring an additional 6,149 shares in the last quarter. Neo Ivy Capital Management purchased a new stake in shares of IQVIA in the third quarter valued at approximately $470,000. Brown Financial Advisors increased its holdings in shares of IQVIA by 13.0% in the third quarter. Brown Financial Advisors now owns 3,432 shares of the medical research company’s stock valued at $813,000 after purchasing an additional 396 shares during the last quarter. Coldstream Capital Management Inc. lifted its position in IQVIA by 14.3% during the third quarter. Coldstream Capital Management Inc. now owns 3,477 shares of the medical research company’s stock worth $815,000 after buying an additional 436 shares in the last quarter. Finally, MidWestOne Financial Group Inc. boosted its stake in IQVIA by 5.1% during the third quarter. MidWestOne Financial Group Inc. now owns 4,786 shares of the medical research company’s stock worth $1,134,000 after buying an additional 232 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IQV has been the topic of several analyst reports. Redburn Atlantic initiated coverage on IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price target on the stock. Bank of America reduced their target price on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday. Truist Financial dropped their price target on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a research note on Thursday. Leerink Partners reiterated an “outperform” rating and issued a $248.00 price objective (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Finally, JPMorgan Chase & Co. cut their target price on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $256.19.

IQVIA Stock Down 0.7 %

Shares of NYSE:IQV opened at $199.06 on Friday. The firm’s 50-day moving average is $212.24 and its two-hundred day moving average is $224.21. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The firm has a market capitalization of $36.13 billion, a PE ratio of 26.12, a price-to-earnings-growth ratio of 2.07 and a beta of 1.49.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.